香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本通告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 臨時股東大會通告 主席 茲通告上海復宏漢霖生物技術股份有限公司（「本公司」）謹訂於2025年8月29日 （星期五）下午4時正假座中國上海市徐匯區宜州路188號B8幢10樓會議室舉行臨時股東 大會（「臨時股東大會」），以考慮及酌情通過下列決議案。除非另有界定，否則本通告 所用詞彙與本公司日期為2025年8月12日之通函所定義者具相同涵義： 普通決議案 – 1 – 1. 考慮及批准有關重新委任及委任第四屆董事會董事之決議案： 1.1 重新委任現屆執行董事朱俊博士為第四屆董事會執行董事； 1.2 重新委任現屆非執行董事Wenjie Zhang先生為第四屆董事會非執行董 事； 1.3 重新委任現屆非執行董事陳啟宇先生為第四屆董事會非執行董事； 1.4 ...

此乃要件 請即處理 閣下如對本通函任何方面或應採取之行動有任何疑問，應諮詢股票經紀或其他註冊證券商、銀行經理、律師、專業會 計師或其他專業顧問。 閣下如已出售或轉讓名下所有上海復宏漢霖生物技術股份有限公司之股份，應立即將本通函連同隨附之代表委任表格 送交買主或承讓人，或經手買賣或轉讓之銀行、股票經紀或其他代理商，以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準確性或完整性亦不發表任何 聲明，並表明概不就因本通函全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） (1)建議委任第四屆董事會董事 (2)建議委任第四屆監事會股東代表監事 (3)建議修訂公司章程 (4)建議修訂《股東大會議事規則》 (5)建議修訂《董事會議事規則》 (6)建議修訂《監事會議事規則》 (7)建議修訂《防止控股股東及其關聯方╱關連人士佔用公司資金制度》 (8)建議修訂《利潤分配管理制度》 及 臨時股東大會 ...

Group 1 - The company Huahong Hanhlin (02696) announced the appointment of its fourth board of directors, with Dr. Zhu Jun continuing as an executive director and three non-executive directors joining, including prominent figures from Fosun Pharma and former GE Healthcare executives, which will enhance the company's global strategy and innovation pipeline [1] - Huahong Hanhlin has shown strong growth, with six products approved in China and four launched overseas, benefiting over 800,000 patients across more than 50 countries [1] - The company's stock price has increased by over 200% since 2025 and was included in the MSCI Global Small Cap Index in May, indicating rising market recognition [1] Group 2 - The company has made significant progress in its core product pipeline, with the PD-L1 ADC HLX43 for advanced NSCLC receiving approval for international multi-center Phase II clinical trials in multiple countries, and initial dosing completed [2] - The I phase clinical data for HLX43 was presented at the 2025 ASCO annual meeting, showing promising efficacy and safety, with a competitive edge in development [2] - The innovative dual-pathway anti-HER2 monoclonal antibody HLX22 is advancing in international Phase III studies for HER2-positive advanced gastric cancer, and a Phase II trial for HER2 low-expressing HR-positive breast cancer has also commenced [2]

Group 1 - The company proposed the reappointment of current executive director Dr. Zhu Jun for the fourth board of directors [1] - The company suggested the reappointment of current non-executive directors Mr. Wenjie Zhang, Mr. Chen Qiyu, Ms. Guan Xiaohui, and Dr. Xingli Wang for the fourth board of directors [1] - The company recommended the reappointment of current independent non-executive directors Mr. Su Deyang, Dr. Chen Liyuan, and Dr. Song Ruilin for the fourth board of directors [1] Group 2 - The supervisory board proposed the reappointment of current shareholder representative supervisors Ms. Feng Rongli and Mr. Kong Deli for the fourth supervisory board [1] - Ms. Feng Rongli and Mr. Kong Deli will continue to perform their supervisory duties until the temporary shareholders' meeting elects the members of the fourth supervisory board [1] - The current employee representative supervisor Mr. Liu Zhiyong was reappointed for the fourth supervisory board at the employee representative meeting scheduled for August 8, 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 建議委任第四屆董事會董事 建議委任第四屆監事會股東代表監事 及 委任職工代表監事 建議重新委任及委任第四屆董事會董事 第三屆董事會的任期於近期屆滿，各董事將繼續履行彼等的董事職責，直至選 舉產生第四屆董事會成員之臨時股東大會結束。 董事會現時由十一名董事組成，包括一名執行董事、六名非執行董事及四名獨立 非執行董事。第三屆董事會的任期於近期屆滿，各董事將繼續履行彼等作為董事 的職責，直至選舉產生第四屆董事會成員之臨時股東大會結束。 董事會建議第四屆董事會由十一名董事組成，其中包括一名執行董事、六名非 執行董事及四名獨立非執行董事。董事會已審議及批准重新委任及委任以下第 四屆董事會董事候選人： 董事會建議(i)重新委任現屆執行董事朱俊博士為第四屆董 ...

Major Events - Silver诺医药-B (02591) is set to conduct an IPO from August 7 to August 12, with an expected listing date of August 15 [1] - Boan Biotech (06955) plans to place 48 million shares at a discount of approximately 8.78%, aiming to raise about HKD 780 million [1] - Derin Holdings (01709) intends to raise HKD 653.3 million, focusing on the development of blockchain, RWA, and virtual asset businesses [1] - Fuhong Hanlin (02696) received FDA approval to initiate a Phase 1 clinical trial for HLX43, a PD-L1 targeted antibody-drug conjugate for thymic cancer treatment [1] - China Biopharmaceutical (01177) obtained NMPA approval for the Phase II clinical trial application of LM-24C5, a dual antibody targeting CEACAM5/4-1BB [1] Financial Reports - China Mobile (00941) reported a shareholder profit of HKD 84.235 billion, a year-on-year increase of 5.03% [1] - Manulife Financial-S (00945) announced a core profit of CAD 1.7 billion for the second quarter [1] - Swire Properties (01972) reported a basic profit attributable to shareholders of HKD 4.42 billion, a year-on-year growth of 15% [1] - Hutchison Whampoa (00013) posted a net profit of USD 455 million, a significant year-on-year increase of 1663.32% [1] - MGM China (02282) disclosed a net profit of HKD 2.383 billion, a year-on-year decrease of 11.25% [1] - SMIC (00981) reported a shareholder profit of USD 132 million for the second quarter, with a revenue guidance for the third quarter indicating a sequential growth of 5% to 7% [1] - Zai Lab (09688) achieved a total revenue of approximately USD 216 million for the first half of the year, reflecting a year-on-year growth of 15.35% [1] - Innovent Biologics (01801) reported total product revenue exceeding RMB 5.2 billion for the first half of the year, maintaining a strong growth rate of over 35% [1] - Pacific Basin Shipping (02343) announced a profit attributable to shareholders of USD 25.6 million, a year-on-year decrease of 56% [1] - Lee & Man Paper Manufacturing (02314) reported a net profit of HKD 811 million, a year-on-year increase of 0.7%, with an interim dividend of HKD 0.066 per share [1] - Swire Group reported a profit attributable to shareholders of HKD 815 million for the first half of the year, a year-on-year decrease of 79% [1] - Lee & Man Chemical Company (00746) reported a profit increase of 36.0% to HKD 327 million, with an interim dividend of HKD 0.195 per share [1] - Hua Hong Semiconductor (01347) reported a profit attributable to parent company owners of USD 7.952 million for the second quarter, a year-on-year increase of 19.2% [1] - Wharf Real Estate Investment (01997) reported a loss attributable to shareholders of HKD 2.406 billion, a year-on-year increase of 128.71%, with the first interim dividend of HKD 0.066 per share [1] - Dekang Agriculture (02419) issued a profit warning, expecting a year-on-year increase in fair value adjustments of biological assets to approximately RMB 1.1 billion to 1.4 billion [1] - Mongol Mining (00975) issued a profit warning, anticipating a net loss of approximately USD 15 million to 25 million for the first half of the year, marking a shift from profit to loss [1] - Dongfeng Motor Group (00489) issued a profit warning, expecting a decline in net profit attributable to the parent company of 90% to 95% for the first half of the year [1]

Core Viewpoint - The company, Fuhong Hanlin (02696.HK), has received FDA approval to initiate a Phase 1 clinical trial for HLX43, a targeted PD-L1 antibody-drug conjugate, for the treatment of thymic carcinoma (TC) [1] Group 1 - HLX43 is a novel targeted PD-L1 antibody-drug conjugate developed by the company, combining a licensed DNA topoisomerase I inhibitor small molecule toxin with a self-developed PD-L1 targeting antibody [1] - The company plans to conduct clinical trials for the TC indication in countries such as Australia, Japan, and the United States once conditions are met [1] - As of the announcement date, there are no approved PD-L1 targeted antibody-drug conjugates available globally [1]

Core Viewpoint - The company, Fuhong Hanlin (02696), has received FDA approval to initiate a Phase 1 clinical trial for HLX43, a PD-L1 targeted antibody-drug conjugate, for the treatment of thymic carcinoma (TC) [1] Group 1 - The FDA approval allows the company to proceed with further clinical-related work for HLX43 [1] - The company plans to conduct clinical trials for thymic carcinoma in countries such as Australia, Japan, and the United States once conditions are met [1]

Core Viewpoint - The company, Junshi Biosciences (复宏汉霖), has received FDA approval to initiate a Phase 1 clinical trial for HLX43, a PD-L1 targeted antibody-drug conjugate, for the treatment of thymic carcinoma (TC) [1] Group 1 - The FDA has approved the clinical trial for HLX43, allowing the company to proceed with further clinical-related work [1] - The company plans to conduct clinical trials for thymic carcinoma in countries such as Australia, Japan, and the United States once conditions are met [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 本公司董事會（「董事會」）欣然宣佈，近日，注射用HLX43（靶向PD-L1抗體 偶聯藥物）（「HLX43」）獲美國食品藥品管理局(FDA)批准開展用於治療胸腺 癌(TC)的1期臨床試驗，可繼續推進後續臨床相關工作。本公司擬於條件具 備後於澳大利亞、日本、美國等國家開展胸腺癌(TC)適應症相關臨床試驗。 B. 關於HLX43 HLX43是由本公司利用許可引進的新型DNA拓撲異構酶I抑制劑小分子毒 素－肽鏈連接符與本公司自主研發的靶向PD-L1的抗體進行偶聯開發的靶向 PD-L1的抗體偶聯藥物(ADC)，擬用於晚期/轉移性實體瘤的治療。截至本公 告日，HLX43及相關聯合療法的最新進展情況如下： | 產品/聯合療法 | 適應症 | 最新進展 | | ...